NASDAQ:AXNX

Axonics Modulation Technologies Competitors

$60.13
+0.13 (+0.22 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$58.08
Now: $60.13
$60.40
50-Day Range
$50.31
MA: $56.30
$60.00
52-Week Range
$26.29
Now: $60.13
$61.16
Volume368,964 shs
Average Volume573,461 shs
Market Capitalization$2.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.02

Competitors

Axonics Modulation Technologies (NASDAQ:AXNX) Vs. PEN, HRC, GMED, HAE, INSP, and IART

Should you be buying AXNX stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Axonics Modulation Technologies, including Penumbra (PEN), Hill-Rom (HRC), Globus Medical (GMED), Haemonetics (HAE), Inspire Medical Systems (INSP), and Integra LifeSciences (IART).

Axonics Modulation Technologies (NASDAQ:AXNX) and Penumbra (NYSE:PEN) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

84.2% of Axonics Modulation Technologies shares are held by institutional investors. Comparatively, 88.2% of Penumbra shares are held by institutional investors. 25.7% of Axonics Modulation Technologies shares are held by company insiders. Comparatively, 8.9% of Penumbra shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Axonics Modulation Technologies and Penumbra, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axonics Modulation Technologies00703.00
Penumbra02402.67

Axonics Modulation Technologies currently has a consensus target price of $64.25, suggesting a potential upside of 6.85%. Penumbra has a consensus target price of $279.00, suggesting a potential upside of 2.56%. Given Axonics Modulation Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Axonics Modulation Technologies is more favorable than Penumbra.

Profitability

This table compares Axonics Modulation Technologies and Penumbra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axonics Modulation Technologies-76.62%-28.05%-23.44%
Penumbra-1.79%-0.12%-0.09%

Volatility & Risk

Axonics Modulation Technologies has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Valuation and Earnings

This table compares Axonics Modulation Technologies and Penumbra's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axonics Modulation Technologies$13.82 million180.66$-79,930,000.00($2.80)-21.48
Penumbra$547.41 million18.11$48.46 million$0.98277.58

Penumbra has higher revenue and earnings than Axonics Modulation Technologies. Axonics Modulation Technologies is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Summary

Penumbra beats Axonics Modulation Technologies on 8 of the 14 factors compared between the two stocks.

Axonics Modulation Technologies (NASDAQ:AXNX) and Hill-Rom (NYSE:HRC) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

84.2% of Axonics Modulation Technologies shares are held by institutional investors. Comparatively, 83.8% of Hill-Rom shares are held by institutional investors. 25.7% of Axonics Modulation Technologies shares are held by company insiders. Comparatively, 0.7% of Hill-Rom shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Axonics Modulation Technologies and Hill-Rom, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axonics Modulation Technologies00703.00
Hill-Rom01602.86

Axonics Modulation Technologies currently has a consensus target price of $64.25, suggesting a potential upside of 6.85%. Hill-Rom has a consensus target price of $121.00, suggesting a potential upside of 7.14%. Given Hill-Rom's higher possible upside, analysts clearly believe Hill-Rom is more favorable than Axonics Modulation Technologies.

Profitability

This table compares Axonics Modulation Technologies and Hill-Rom's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axonics Modulation Technologies-76.62%-28.05%-23.44%
Hill-Rom7.74%22.71%8.01%

Volatility & Risk

Axonics Modulation Technologies has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Comparatively, Hill-Rom has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

Valuation and Earnings

This table compares Axonics Modulation Technologies and Hill-Rom's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axonics Modulation Technologies$13.82 million180.66$-79,930,000.00($2.80)-21.48
Hill-Rom$2.88 billion2.60$223 million$5.5320.42

Hill-Rom has higher revenue and earnings than Axonics Modulation Technologies. Axonics Modulation Technologies is trading at a lower price-to-earnings ratio than Hill-Rom, indicating that it is currently the more affordable of the two stocks.

Summary

Hill-Rom beats Axonics Modulation Technologies on 9 of the 14 factors compared between the two stocks.

Axonics Modulation Technologies (NASDAQ:AXNX) and Globus Medical (NYSE:GMED) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Axonics Modulation Technologies and Globus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axonics Modulation Technologies-76.62%-28.05%-23.44%
Globus Medical12.36%9.85%9.04%

Valuation and Earnings

This table compares Axonics Modulation Technologies and Globus Medical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axonics Modulation Technologies$13.82 million180.66$-79,930,000.00($2.80)-21.48
Globus Medical$785.37 million8.51$155.21 million$1.6839.88

Globus Medical has higher revenue and earnings than Axonics Modulation Technologies. Axonics Modulation Technologies is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Axonics Modulation Technologies and Globus Medical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axonics Modulation Technologies00703.00
Globus Medical041002.71

Axonics Modulation Technologies currently has a consensus target price of $64.25, suggesting a potential upside of 6.85%. Globus Medical has a consensus target price of $66.40, suggesting a potential downside of 0.90%. Given Axonics Modulation Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Axonics Modulation Technologies is more favorable than Globus Medical.

Insider & Institutional Ownership

84.2% of Axonics Modulation Technologies shares are held by institutional investors. Comparatively, 64.4% of Globus Medical shares are held by institutional investors. 25.7% of Axonics Modulation Technologies shares are held by company insiders. Comparatively, 25.6% of Globus Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Axonics Modulation Technologies has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Summary

Globus Medical beats Axonics Modulation Technologies on 9 of the 14 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and Axonics Modulation Technologies (NASDAQ:AXNX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares Haemonetics and Axonics Modulation Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Haemonetics11.76%22.85%10.40%
Axonics Modulation Technologies-76.62%-28.05%-23.44%

Valuation & Earnings

This table compares Haemonetics and Axonics Modulation Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Haemonetics$988.48 million6.02$76.53 million$3.3135.37
Axonics Modulation Technologies$13.82 million180.66$-79,930,000.00($2.80)-21.48

Haemonetics has higher revenue and earnings than Axonics Modulation Technologies. Axonics Modulation Technologies is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Haemonetics and Axonics Modulation Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Haemonetics00403.00
Axonics Modulation Technologies00703.00

Haemonetics currently has a consensus target price of $144.80, suggesting a potential upside of 23.70%. Axonics Modulation Technologies has a consensus target price of $64.25, suggesting a potential upside of 6.85%. Given Haemonetics' higher possible upside, equities research analysts plainly believe Haemonetics is more favorable than Axonics Modulation Technologies.

Insider and Institutional Ownership

96.2% of Haemonetics shares are owned by institutional investors. Comparatively, 84.2% of Axonics Modulation Technologies shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by company insiders. Comparatively, 25.7% of Axonics Modulation Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Haemonetics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Axonics Modulation Technologies has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500.

Summary

Haemonetics beats Axonics Modulation Technologies on 10 of the 13 factors compared between the two stocks.

Inspire Medical Systems (NYSE:INSP) and Axonics Modulation Technologies (NASDAQ:AXNX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares Inspire Medical Systems and Axonics Modulation Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inspire Medical Systems-61.07%-32.23%-26.42%
Axonics Modulation Technologies-76.62%-28.05%-23.44%

Valuation & Earnings

This table compares Inspire Medical Systems and Axonics Modulation Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspire Medical Systems$82.05 million72.33$-33,240,000.00($1.40)-156.04
Axonics Modulation Technologies$13.82 million180.66$-79,930,000.00($2.80)-21.48

Inspire Medical Systems has higher revenue and earnings than Axonics Modulation Technologies. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Axonics Modulation Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Inspire Medical Systems and Axonics Modulation Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inspire Medical Systems03802.73
Axonics Modulation Technologies00703.00

Inspire Medical Systems currently has a consensus target price of $168.5455, suggesting a potential downside of 22.84%. Axonics Modulation Technologies has a consensus target price of $64.25, suggesting a potential upside of 6.85%. Given Axonics Modulation Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Axonics Modulation Technologies is more favorable than Inspire Medical Systems.

Insider and Institutional Ownership

96.3% of Inspire Medical Systems shares are owned by institutional investors. Comparatively, 84.2% of Axonics Modulation Technologies shares are owned by institutional investors. 6.6% of Inspire Medical Systems shares are owned by company insiders. Comparatively, 25.7% of Axonics Modulation Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Inspire Medical Systems has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Axonics Modulation Technologies has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500.

Integra LifeSciences (NASDAQ:IART) and Axonics Modulation Technologies (NASDAQ:AXNX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares Integra LifeSciences and Axonics Modulation Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Integra LifeSciences4.10%14.26%5.77%
Axonics Modulation Technologies-76.62%-28.05%-23.44%

Valuation & Earnings

This table compares Integra LifeSciences and Axonics Modulation Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integra LifeSciences$1.52 billion3.90$50.20 million$2.7425.59
Axonics Modulation Technologies$13.82 million180.66$-79,930,000.00($2.80)-21.48

Integra LifeSciences has higher revenue and earnings than Axonics Modulation Technologies. Axonics Modulation Technologies is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Integra LifeSciences and Axonics Modulation Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Integra LifeSciences14402.33
Axonics Modulation Technologies00703.00

Integra LifeSciences currently has a consensus target price of $67.8889, suggesting a potential downside of 3.18%. Axonics Modulation Technologies has a consensus target price of $64.25, suggesting a potential upside of 6.85%. Given Axonics Modulation Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Axonics Modulation Technologies is more favorable than Integra LifeSciences.

Insider and Institutional Ownership

85.7% of Integra LifeSciences shares are owned by institutional investors. Comparatively, 84.2% of Axonics Modulation Technologies shares are owned by institutional investors. 4.3% of Integra LifeSciences shares are owned by company insiders. Comparatively, 25.7% of Axonics Modulation Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Integra LifeSciences has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Axonics Modulation Technologies has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500.

Summary

Integra LifeSciences beats Axonics Modulation Technologies on 9 of the 14 factors compared between the two stocks.


Axonics Modulation Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Penumbra logo
PEN
Penumbra
1.5$272.03+0.0%$9.92 billion$547.41 million-1,007.52
Hill-Rom logo
HRC
Hill-Rom
1.8$112.94+1.4%$7.49 billion$2.88 billion34.02
Globus Medical logo
GMED
Globus Medical
1.4$67.00+1.1%$6.69 billion$785.37 million72.83News Coverage
Haemonetics logo
HAE
Haemonetics
1.6$117.06+2.8%$5.95 billion$988.48 million56.55
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.2$218.45+3.3%$5.93 billion$82.05 million-94.16
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$70.12+0.9%$5.92 billion$1.52 billion104.66
Inari Medical logo
NARI
Inari Medical
1.1$113.64+0.2%$5.54 billionN/A0.00Insider Selling
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.6$87.99+0.0%$5.50 billion$362.30 million-108.63
Nevro logo
NVRO
Nevro
1.2$147.08+0.9%$5.09 billion$390.26 million-54.07
ShockWave Medical logo
SWAV
ShockWave Medical
1.2$137.01+0.7%$4.77 billion$42.93 million-67.83
ICU Medical logo
ICUI
ICU Medical
1.5$204.19+0.1%$4.33 billion$1.27 billion54.02
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.6$132.76+1.3%$3.87 billion$214.55 million-69.51
Glaukos logo
GKOS
Glaukos
0.9$83.13+3.3%$3.81 billion$236.98 million-50.38Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
Cantel Medical logo
CMD
Cantel Medical
1.3$83.76+0.5%$3.54 billion$1.02 billion99.72Insider Selling
NuVasive logo
NUVA
NuVasive
1.1$68.71+1.7%$3.53 billion$1.17 billion-312.32
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.50+1.5%$3.42 billion$994.85 million-116.04News Coverage
AtriCure logo
ATRC
AtriCure
1.5$65.90+1.0%$3.00 billion$230.81 million-57.30
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$8.72+0.9%$1.82 billion$4.11 million-6.41
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99+0.2%$1.75 billion$88.02 million-58.51
Silk Road Medical logo
SILK
Silk Road Medical
1.1$50.14+0.7%$1.72 billion$63.35 million-41.10
Alphatec logo
ATEC
Alphatec
0.8$17.60+1.3%$1.67 billion$113.43 million-16.00Analyst Report
News Coverage
Luminex logo
LMNX
Luminex
1.8$32.95+2.0%$1.56 billion$334.64 million84.49News Coverage
Gap Up
Pulmonx logo
LUNG
Pulmonx
1.4$43.48+4.7%$1.55 billion$32.60 million0.00Insider Selling
Gap Down
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.13+0.8%$1.45 billion$236.54 million-54.74
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.72+5.0%$1.42 billion$299.26 million-13.53Gap Up
Atrion logo
ATRI
Atrion
1.1$644.00+0.3%$1.18 billion$155.07 million36.28
SI-BONE logo
SIBN
SI-BONE
1.2$33.76+0.5%$1.10 billion$67.30 million-21.10Insider Selling
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$54.00+0.9%$1.06 billion$189.49 million-120.00News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$51.44+2.0%$1.06 billion$117.23 million55.31
Cerus logo
CERS
Cerus
1.7$6.13+1.0%$1.03 billion$74.65 million-15.72Analyst Upgrade
Analyst Revision
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.55+0.0%$974.05 million$72.55 million-34.41Analyst Report
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.77+1.7%$906.52 million$264.16 million-5.32
CryoLife logo
CRY
CryoLife
2.0$22.61+0.1%$884.50 million$276.22 million-59.50
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.87+1.6%$836.48 million$459.95 million35.73
Surmodics logo
SRDX
Surmodics
1.3$57.14+0.9%$786.02 million$94.86 million714.25
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42+0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10+0.5%$689.46 million$123.86 million68.34Analyst Upgrade
Intersect ENT logo
XENT
Intersect ENT
1.4$20.49+1.7%$676.50 million$109.14 million-10.73News Coverage
SeaSpine logo
SPNE
SeaSpine
1.3$21.94+2.1%$612.85 million$159.08 million-13.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Vapotherm logo
VAPO
Vapotherm
1.5$23.26+0.7%$600.27 million$48.10 million-11.08News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80+1.7%$570.33 million$114.51 million-84.68News Coverage
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.81+1.0%$568.96 millionN/A-9.61Analyst Downgrade
News Coverage
PAVmed logo
PAVM
PAVmed
1.2$6.00+1.8%$494.77 millionN/A-7.89
Accuray logo
ARAY
Accuray
2.3$5.21+0.6%$484.00 million$382.93 million37.21
iCAD logo
ICAD
iCAD
1.5$18.55+1.0%$462.23 million$31.34 million-19.53Analyst Upgrade
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$22.12+1.9%$457.29 million$11.22 million-50.27Gap Down
AVITA Medical logo
RCEL
AVITA Medical
1.4$21.07+0.2%$455.72 million$14.26 million-10.18Analyst Upgrade
Profound Medical logo
PROF
Profound Medical
1.6$20.50+3.9%$415.95 million$4.17 million-17.52News Coverage
Soliton logo
SOLY
Soliton
1.1$18.25+0.1%$386.90 millionN/A-24.33
Cytosorbents logo
CTSO
Cytosorbents
1.7$8.90+0.2%$385.05 million$24.95 million-26.97
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.